Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cetolán is a topical over-the-counter (OTC) analgesic gel developed and marketed by Laboratorios Columbia. Its primary active ingredient is ketorolac tromethamine, a nonsteroidal anti-inflammatory drug (NSAID) that provides local relief from pain and inflammation. The drug functions by inhibiting the cyclooxygenase enzymes (COX-1 and COX-2), which are responsible for the synthesis of prostaglandins that mediate the inflammatory response and pain signaling. Cetolán is specifically indicated for the local treatment of mild to moderate musculoskeletal pain, including conditions such as sprains, strains, and minor sports injuries. It is formulated as a 2% gel for direct application to the affected area, allowing for localized therapeutic effects with minimal systemic absorption compared to oral NSAIDs.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cetolán.